Assessing the Evidence: A Case Based Analysis Focused on Myelofibrosis - Gainesville, GA

Hematology-Oncology
Curriculum:
Diagnosis of a Potential Myeloproliferative Neoplasm
Credits:
1 ACPE 1 ANCC Contact Hours 1 AMA PRA Category 1 Credit(s)™
Launch Date:
April 03, 2013
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Oncology Practitioners

Relevant Terms:

Myelofibrosis

Ross Levine, MD 

Ross Levine, MD
Human Oncology & Pathogenesis Program
Leukemia Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY

Ross Levine is an Assistant Member in Memorial Sloan Kettering's Human Oncology and Pathogenesis Program and also holds an appointment on the Leukemia Service in the Department of Medicine at MSKCC. While working in the laboratory of Gary Gilliland at Harvard Medical School, Dr. Levine, along with three other groups, identified JAK2 mutations in patients with polycythemia vera, essential thrombocytosis, and myelofibrosis. His laboratory focuses to improve the understanding of the genetic basis for activation of signal transduction pathways in myeloid malignancies, and to use this knowledge to improve therapies for patients with these disorders. Dr. Levine is an investigator of projects 1 and 2. 

Brady L. Stein, MD, MHS 

Brady L. Stein, MD, MHS
Assistant Professor, Medicine
Hematology Oncology Division
Feinberg School of Medicine
Northwestern University
Chicago, IL

Dr. Stein is interested in the clinical investigation and clinical epidemiology of the classical Myeloproliferative Neoplasms. He has focused on the correlation between molecular and genetic abnormalities and clinical phenotype in these disorders, as well as the influence of gender on disease manifestations. He currently serves as the institutional PI for an international consortium (MPD-RC) as well as the institutional PI for JAK-inhibitor studies in patients with Myelofibrosis and Polycythemia Vera.

Michael Mauro, MD 

Michael Mauro, MD 
Professor of Medicine
Division of Hematology and Medical Oncology
Oregon Health Science University
Portland, OR 

Michael Mauro, MD, is Professor of Medicine in the Division of Hematology and Medical Oncology at Oregon Health Science University. He received his medical degree from Dartmouth Medical School in New Hampshire and went on to complete his residency at New York Hospital-Cornell University Medical Center. Dr. Mauro's clinical focus is leukemia, with a particular interest in CML.

Janet Oishi, RN, MN, OCN

Janet Oishi, RN, MN, OCN
Oncology Nurse
Seattle Cancer Care Alliance
Seattle, WA
Serves as the recognized Nurse Planner for this activity

1. Analyze updated diagnostic criteria for myelofibrosis (MF) and their role in managing individual patients 
2. Incorporate the use of International Prognostic Scoring System (IPSS) and updated Dynamic International Prognostic Scoring System (DIPSS) Plus scoring of prognostic factors into the management of patients with MF 
3. Identify the role of JAK pathway inhibition and its potential role in clinical practice 
4. Evaluate safety and efficacy data for currently available MF-targeted therapies 

This activity is supported by an unrestricted education grant from Incyte Corporation.


This activity is sponsored by the Institute for Continuing Healthcare Education. 

Release Date: April 5, 2013
Expiration Date: October 5, 2013

Learning Objectives
  • Analyze updated diagnostic criteria for myelofibrosis (MF) and their role in managing individual patients
  • Incorporate the use of International Prognostic Scoring System (IPSS) and updated Dynamic International Prognostic Scoring System (DIPSS) Plus scoring of prognostic factors into the management of patients with MF
  • Identify the role of JAK pathway inhibition and its potential role in clinical practice
  • Evaluate safety and efficacy data for currently available MF-targeted therapies 

Physician Accreditation
The Institute for Continuing Healthcare Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Institute for Continuing Healthcare Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
 
Nurse Accreditation
Institute for Continuing Healthcare Education is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This activity offers 1.0 contact hours to participating nurses. This credit may be applied toward licensure requirements in those states that recognize American Nurses Credentialing Center's Commission on Accreditation (ANCC-COA) accredited providers.

Accreditation applies solely to educational activities and does not imply approval or endorsement of any commercial product by the ANCC-COA. 

Pharmacist Accreditation
The Institute for Continuing Healthcare Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is acceptable for 1.0 hour (0.1 CEU) of continuing education credit in states that recognize ACPE accredited providers.

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.

Activity Type: Knowledge-based
 ACPE # 0781-000013-001-L01-P

Disclosures
Relationships are abbreviated as follows: E, Educational Planning Committee; G, Grant/research support recipient; A, Advisor/review panel member/educational planning committee; C, Consultant/Independent Contractor; SS, Stock shareholder; SB, Speaker bureau; PE, Promotional Event Talks; H, Honoraria; O, Other.

Faculty
Ross Levine, MD, has disclosed that he has no relevant financial relationships specific to the subject matter of this activity that have occurred within the past 12 months.

Brady Stein, MD, has disclosed the following relevant financial relationships that have occurred within the past 12 months: Incyte/A, SB; Hoffman-La Roche/H.

Michael Mauro, MD, has disclosed the following relevant financial relationships that have occurred within the past 12 months: Ariad Pharmaceuticals, Bristol Myers Squibb, Novartis, Pfizer/A.
 
Janet Oishi, RN, MN, OCN, has disclosed the she has no relevant financial relationships that have occurred within the past 12 months.

Activity Development and Management Team
Cathy Pagano, CCMEP; Allison A. Muller, Pharm.D, D.ABAT; Scott Kober, CCMEP; April Reynolds, MS, ELS; Sandra Davidson; and Tina Chiu, MEd; are employees of the Institute and have no relationships to disclose.

Off-label Product Disclosure
This educational activity includes discussion of published and/or investigational uses of agents that are not indicated by the U.S. Food and Drug Administration.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

COURSE VIEWING REQUIREMENTS
Google Chrome for Windows, Mac, or Linux
Internet Explorer 7.0+ for Windows
Mozilla 1.4+ for Windows, Mac, or Linux
Firefox 3.5+ for Windows, Mac, or Linux
Safari 4.0+ for Mac
 
For additional technical support, please send an email to tchiu@iche.edu 

General Disclosure and Copyright Statement
The opinions expressed in this publication are those of the participating faculty and not those of the Institute for Continuing Healthcare Education (the Institute), Incyte, or any manufacturers of products mentioned herein.

This information is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a healthcare professional regarding diagnostic and treatment options of a specific patient's medical condition. In no event will the Institute be responsible for any decision made or action taken based upon the information provided in this
activity.

Participants are encouraged to consult the package insert for all products for updated information and changes regarding indications, dosages, and contraindications. This recommendation is particularly important for new or infrequently used products.

Copyright 2013. Institute for Continuing Healthcare Education (the Institute). All rights reserved. No part of this publication may be reproduced or transmitted in any other form or by any means electronic or mechanical—without first obtaining written permission from the Institute.
 
The Institute reserves the right to cancel or modify the activity content, faculty, and activities if necessary.